These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 32859199)
21. Effective Functional Immunogenicity of a DNA Vaccine Combination Delivered via In Vivo Electroporation Targeting Malaria Infection and Transmission. Cao Y; Hayashi CTH; Zavala F; Tripathi AK; Simonyan H; Young CN; Clark LC; Usuda Y; Van Parys JM; Kumar N Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891298 [TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults. Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674 [TBL] [Abstract][Full Text] [Related]
24. Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. de Graaf H; Payne RO; Taylor I; Miura K; Long CA; Elias SC; Zaric M; Minassian AM; Silk SE; Li L; Poulton ID; Baker M; Draper SJ; Gbesemete D; Brendish NJ; Martins F; Marini A; Mekhaiel D; Edwards NJ; Roberts R; Vekemans J; Moyle S; Faust SN; Berrie E; Lawrie AM; Hill F; Hill AVS; Biswas S Front Immunol; 2021; 12():694759. PubMed ID: 34335606 [TBL] [Abstract][Full Text] [Related]
25. Identification of domains within Pfs230 that elicit transmission blocking antibody responses. Tachibana M; Miura K; Takashima E; Morita M; Nagaoka H; Zhou L; Long CA; Richter King C; Torii M; Tsuboi T; Ishino T Vaccine; 2019 Mar; 37(13):1799-1806. PubMed ID: 30824357 [TBL] [Abstract][Full Text] [Related]
28. Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes. Patra KP; Li F; Carter D; Gregory JA; Baga S; Reed SG; Mayfield SP; Vinetz JM Infect Immun; 2015 May; 83(5):1799-808. PubMed ID: 25690099 [TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes. Federizon J; Frye A; Huang WC; Hart TM; He X; Beltran C; Marcinkiewicz AL; Mainprize IL; Wills MKB; Lin YP; Lovell JF Vaccine; 2020 Jan; 38(4):942-950. PubMed ID: 31727504 [TBL] [Abstract][Full Text] [Related]
30. A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses. Jones RM; Chichester JA; Manceva S; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V Hum Vaccin Immunother; 2015; 11(1):124-32. PubMed ID: 25483525 [TBL] [Abstract][Full Text] [Related]
31. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A Malar J; 2007 Aug; 6():107. PubMed ID: 17686163 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant Parzych EM; Miura K; Ramanathan A; Long CA; Burns JM Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993460 [TBL] [Abstract][Full Text] [Related]
33. Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding. Kumar R; Angov E; Kumar N Infect Immun; 2014 Apr; 82(4):1453-9. PubMed ID: 24421036 [TBL] [Abstract][Full Text] [Related]
34. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi. Pirahmadi S; Zakeri S; A Mehrizi A; D Djadid N; Raz AA; J Sani J; Abbasi R; Ghorbanzadeh Z Malar J; 2019 Apr; 18(1):146. PubMed ID: 31014347 [TBL] [Abstract][Full Text] [Related]
35. B cell clonal expansion and mutation in the immunoglobulin heavy chain variable domain in response to Pfs230 and Pfs25 malaria vaccines. Coelho CH; Galson JD; Trück J; Duffy PE Int J Parasitol; 2022 Oct; 52(11):707-710. PubMed ID: 34896314 [TBL] [Abstract][Full Text] [Related]
36. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate. Radtke AJ; Anderson CF; Riteau N; Rausch K; Scaria P; Kelnhofer ER; Howard RF; Sher A; Germain RN; Duffy P Sci Rep; 2017 Jan; 7():40312. PubMed ID: 28091576 [TBL] [Abstract][Full Text] [Related]
37. Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25. Mlambo G; Maciel J; Kumar N Infect Immun; 2008 May; 76(5):2018-24. PubMed ID: 18316385 [TBL] [Abstract][Full Text] [Related]
38. Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum. Kapulu MC; Da DF; Miura K; Li Y; Blagborough AM; Churcher TS; Nikolaeva D; Williams AR; Goodman AL; Sangare I; Turner AV; Cottingham MG; Nicosia A; Straschil U; Tsuboi T; Gilbert SC; Long CA; Sinden RE; Draper SJ; Hill AV; Cohuet A; Biswas S Sci Rep; 2015 Jun; 5():11193. PubMed ID: 26063320 [TBL] [Abstract][Full Text] [Related]